PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study
Por um escritor misterioso
Descrição
Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration - Vladimir Bantseev, Joshua Horvath, Giulio Barteselli
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect
Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study, Health and Quality of Life Outcomes
PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect
PDF) End of Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real- World Analysis of 49 485 Eyes - ScienceDirect
PDF) Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular AMD Patients: A “Real World” Analysis in 49,485 Eyes
Full article: Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data
Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence
High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
Biomolecules, Free Full-Text
PDF) Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
de
por adulto (o preço varia de acordo com o tamanho do grupo)
